Business Wire

VA-DXC-TECHNOLOGY

21.5.2020 15:02:13 CEST | Business Wire | Press release

Share
DXC Introduces Corporate Incident Response Application to Help Businesses Proactively Reduce Risk

DXC Technology (NYSE: DXC) today introduced its Corporate Incident Response (CIR) application for ServiceNow to enable organizations like Banco Santander, one of the largest retail and commercial banks in the world, and the Nordex Group, one of the world’s largest wind turbine manufacturers, to quickly and proactively identify, address and manage important non-IT corporate incidents, such as those related to facilities, physical security, and environment, health and safety. The application, built on the ServiceNow platform, allows businesses to reduce their risk profiles and overcome situations before they evolve into companywide crises.

The CIR application provides an end-to-end workflow management solution to manage, track and respond to non-IT-related issues in an efficient, standardized manner.

“In today’s world, business disruptions are inevitable. While operational resilience has been around for years, a change in mindset is required in order to prevent, respond to, recover from, and most importantly, learn from and adapt after crises occur,” said Dan Stoks, vice president, Global ServiceNow Practice, DXC Technology. “The Corporate Incident Response application can work with ServiceNow’s integrated risk management and other workflows to enable organizations to securely manage crisis response workflows and risks to the business.”

Key features of the solution:

  • Situation rooms — provide a central point of collaboration for dispersed organizations to orchestrate response teams and plans and monitor and evaluate the overall picture.
  • App notifications — provide the ability to send companywide notifications, such as alerts, push notifications, email and SMS to predefined groups as well as external partners and customers.
  • 360-degree view — provides the management team with a 360-degree view of where the organization stands on corporate-related incidents, so they can make fact-based decisions that reduce their overall risk profile.

Banco Santander Streamlines Crisis Management Systems with DXC CIR Application

Banco Santander wanted a single platform to manage its global facility and security processes and replace its previous system with a new, digitized platform. Using the DXC CIR application with ServiceNow, Santander streamlined its processes with better-performing facility, security and crisis management systems and improved user experiences for its managers and end users. It also benefited from better insights and greater transparency in its global facility and security services.

“The consolidation of existing and new facility management capabilities to a new platform was a crucial part of our business transformation journey,” said Galo Gilarranz Vicente, Real Estate, General Services and Security, Banco Santander. “DXC’s CIR application has allowed us to reduce costs by rationalizing the global application landscape, standardize our processes and increase employee efficiency with automation.”

The Nordex Group Improves Worker Safety with DXC’s Health, Safety and Environmental Management Business Expertise

The Nordex Group tapped the DXC Health, Safety and Environment Suite (HSE) for ServiceNow, which is part of DXC’s CIR portfolio, to create a safety-driven culture throughout its global operations. With the DXC suite, the Nordex Group experienced a more streamlined process to reduce worker hazards and prevent incidents before they occur.

“Nordex is committed to worker safety, implementing proper processes to prevent and quickly respond to work-related incidents,” said Philipp Marten, program manager, Business Systems, Nordex Group. “With DXC’s HSE solution, we were able to reduce the complexity of our system, streamline reporting and create a safer work environment throughout our global operations.”

DXC is offering this application for free for 120 days to complement and enhance the capabilities of ServiceNow Emergency Response Management applications.

“Operational risk management is a crucial part of how ServiceNow enables resilience for our customers for both IT and non-IT operations,” said David Parsons, senior vice president, Global Alliances and Channel Ecosystem, ServiceNow. “Corporate Incident Response from DXC Technology exemplifies the innovative applications that extend the value of the Now Platform and our Risk and Business Continuity portfolio to serve critical and emerging use cases for joint customers enterprise-wide.”

To learn more and download the CIR for ServiceNow application, click here .

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye